H. J. M. J. Crijns

The Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist-exposed Pregnancies Is Similar to the General Population

H. J. M. J. Crijns, Janneke Jentink, Ester Garne et al. · The Journal of Rheumatology · 2011 · 37 citations · Full text

Reported congenital malformations after exposure to non‐tumour necrosis factor inhibitor biologics: A retrospective comparative study in EudraVigilance

Nafise Ghalandari, H. J. M. J. Crijns, Jorieke E. H. Bergman et al. · British Journal of Clinical Pharmacology · 2022 · 22 citations · Full text

The pre‐ and post‐authorisation data published by the European medicines agency on the use of biologics during pregnancy and lactation

Nafise Ghalandari, Radboud J. E. M. Dolhain, Johanna M W Hazes et al. · British Journal of Clinical Pharmacology · 2019 · 21 citations · Full text

Prescriptive contraceptive use among isotretinoin users in the Netherlands in comparison with non‐users: a drug utilisation study

H. J. M. J. Crijns, Nienke van Rein, Christine C. Gispen‐de Wied et al. · Pharmacoepidemiology and Drug Safety · 2012 · 17 citations · Full text

Dilemma of belimumab therapy (dis)continuation during pregnancy: Results of a retrospective study in eudravigilance

Nafise Ghalandari, H. J. M. J. Crijns, Radboud J. E. M. Dolhain et al. · Lupus · 2022 · 16 citations · Full text